Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/JCI81137 http://scihub22266oqcxt.onion/10.1172/JCI81137 C4811123!4811123 !27035813     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27035813 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27035813 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Clin+Invest 2016 ; 126 (4 ): 1224-32 Nephropedia Template TP {{tp|p=27035813 |t=2016. Dendritic cell-derived exosomes for cancer therapy |pdf=|usr=}}{{27035813 }} gab.com Text Dendritic cell-derived exosomes for cancer therapy JO: J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=27035813 #FOAvip DC-derived exosomes (Dex) are nanometer-sized membrane vesicles that are secreted by the sentinel antigen-presenting cells of the immune system: DCs. Like DCs, the molecular composition of Dex includes surface expression of functional MHC-peptide complexes, costimulatory molecules, and other components that interact with immune cells. Dex have the potential to facilitate immune cell-dependent tumor rejection and have distinct advantages over cell-based immunotherapies involving DCs. Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell-based immune responses in patients. This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and the future of Dex immunotherapy for cancer. Twit Text FOAVip Dendritic cell-derived exosomes for cancer therapy ????J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=27035813 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27035813 #FOAvip English Wikipedia <ref>{{Cite pmid|27035813 }}</ref> Dendritic cell-derived exosomes for cancer therapy #MMPMID27035813 Pitt JM ; André F ; Amigorena S ; Soria JC ; Eggermont A ; Kroemer G ; Zitvogel L J Clin Invest 2016[Apr]; 126 (4 ): 1224-32 PMID27035813 show ga DC-derived exosomes (Dex) are nanometer-sized membrane vesicles that are secreted by the sentinel antigen-presenting cells of the immune system: DCs. Like DCs, the molecular composition of Dex includes surface expression of functional MHC-peptide complexes, costimulatory molecules, and other components that interact with immune cells. Dex have the potential to facilitate immune cell-dependent tumor rejection and have distinct advantages over cell-based immunotherapies involving DCs. Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell-based immune responses in patients. This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and the future of Dex immunotherapy for cancer. |*Immunity, Cellular [MESH] |Animals [MESH] |Clinical Trials, Phase I as Topic [MESH] |Clinical Trials, Phase II as Topic [MESH] |Dendritic Cells/*immunology/pathology [MESH] |Exosomes/*immunology/pathology [MESH] |Humans [MESH] |Immunotherapy/*methods [MESH] |Killer Cells, Natural/immunology/pathology [MESH] |Neoplasms/immunology/pathology/*therapy [MESH]Dendritic cell-derived exosomes for cancer therapy (epmc).pdf DeepDyve Pubget Overpricing